News | April 08, 2026
Dabur reports steady domestic growth amid global headwinds in Q4 FY26
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
Collaboration to study integration of AI-enabled VR solutions into medical and nursing curricula
Subscribe To Our Newsletter & Stay Updated
